

Differential Gene Expression and Regulation of Type-1 Angiotensin II Receptor Subtypes in the Rat

Yutaka Kitami, Takafumi Okura, Kazumasa Marumoto,
Rumi Wakamiya and Kunio Hiwada

The 2nd Department of Internal Medicine,
Ehime University School of Medicine, Ehime, Japan

Received September 7, 1992

SUMMARY: A simplified and sensitive method for measuring expression levels of type-1 angiotensin II (AT₁) receptor subtypes, AT_{1A} and AT_{1B}, was established. The two receptor cDNAs were co-amplified and measured by polymerase chain reaction using primers based on the corresponding receptor subtype genes. Both AT_{1A} and AT_{1B} mRNAs were widely expressed in the rat tissues including adrenal gland, kidney, heart, aorta, lung, liver, testis, pituitary gland, cerebrum and cerebellum. AT_{1A} mRNA was predominantly expressed in the rat tissues examined except adrenal gland and pituitary gland where AT_{1B} mRNA was predominantly expressed. Sodium depletion did not change mRNA levels of AT_{1A} and AT_{1B} in the all tissues. However, both AT_{1A} and AT_{1B} mRNA levels in the heart and aorta were down-regulated by treatment with AT₁ specific antagonist, TCV 116. In contrast, AT_{1B} mRNA in the adrenal gland was mainly reduced by the treatment. These results suggest that the expression level of AT_{1B} mRNA in the adrenal gland depends on the activity of the renin-angiotensin-aldosterone system (RAAS) and both receptor subtypes mediate contraction and hypertrophy of the smooth and cardiac muscles via the RAAS. © 1992 Academic Press, Inc.

Angiotensin II (Ang II), which is a biologically active peptide in the renin-angiotensin-aldosterone system (RAAS), plays an important role in the homeostasis of blood pressure, electrolyte balance and cardiovascular hypertrophy (1). Ang II interacts with pharmacologically distinct subtypes of cell-surface receptors, type I (AT₁) and type II (AT₂). AT₁ receptor is a G-protein coupled receptor and mediates the classical functions assigned to Ang II whereas the functions of AT₂ receptor remains uncertain (2).

Recently, AT₁ receptor cDNA (AT_{1A}) has been cloned and characterized from bovine adrenal cells (3) and rat vascular smooth muscle cells (4). Furthermore, the second form of AT₁ receptor cDNA (AT_{1B}), which exhibited a high similarity relative to amino acid sequence of AT_{1A} receptor (95% identity), was cloned from the rat pituitary gland (5). AT₁ receptor subtypes, AT_{1A} and AT_{1B}, mRNAs were widely expressed in the various rat tissues, and the differential tissue expression of the two mRNAs were observed (5, 6).

In this report, we measured expression levels of AT_{1A} and AT_{1B} receptor mRNAs in the various rat tissues using a simplified and sensitive method which we developed. Furthermore, we studied the effects of sodium depletion and an AT₁ receptor specific antagonist, TCV 116, on the expression and regulation of the two receptor mRNAs.

MATERIALS AND METHODS

Animals and treatments

Male Wistar rats (400-450 g) were purchased from Charles River Japan Inc. (Atsugi, Kanagawa, Japan). They were fed a standard laboratory diet (11 mmol Na/ 100g; Oriental Yeast Co., Tokyo, Japan) and tap water for one week before the experiment. Control group (n=3) was fed a standard laboratory diet for one week. Sodium-depleted group (n=3) was fed a low sodium diet (3 mmol Na/100 g; Oriental Yeast Co.) for one week and was administered furosemide (30 mg/kg/day, subcutaneously) on days 4, 5 and 6, as well as 4 hr before killing. AT₁ receptor specific antagonist-treated group (n=3) was fed a standard laboratory diet and was administered TCV 116 (1 mg/kg/day, orally) for one week. At the end of the experiment, all rats were anesthetized with ether and were killed by decapitation. The whole tissues of adrenal gland, aorta and pituitary gland, and small pieces of lung, liver, kidney, left ventricular muscle of heart, testis, cerebrum and cerebellum were removed from individual rats of the three groups. All tissues were immediately snap-frozen in liquid nitrogen and stored at -80 °C until used for the isolation of the tissue total RNA.

Isolation of the tissue total RNA

The tissue total RNA was extracted from each tissue by the protocol of ISOGEN (Nippon Gene Co. Ltd., Tokyo, Japan). The extracted RNA was finally suspended in ribonuclease-free water and was quantified by measuring the absorbance at 260 nm. At the same time, each RNA was subjected to Northern gel electrophoresis to check the quality of RNA.

Measurement for levels of AT₁ receptor subtype mRNAs

The tissue total RNA (20 µg) was subjected to first strand cDNA synthesis in 20 µl of reaction volume using oligo-dT primers (Boehringer

		1	
AT _{1A}	GTGGAGTGAcA.gggttcaaagc <u>acactggcaatgtaatgccctga...</u> ca	1396	
AT _{1B}	GTGGAGTGAGagggttcaaagc <u>ctgcaagtgaagtgatttcctgcacagca</u>	1210	
		3	
AT _{1A}	gaagccaggggcagcct.....ctgactaaatggcttacgaccaaaggacc	1441	
AT _{1B}	gaagccagaggaccatttgggctaagcagctcactcactaccgaaggagt	1260	
AT _{1A}	attcacccctgc.....ctcaggatctaagcagaaaa...atgcgct	1480	
AT _{1B}	gttcaacccccagcaatcctttcagggtgaagcagagaaagcactcagt	1310	
AT _{1A}	catcagactgtagataatgactaaaactctgagagaagactttgaaggag	1530	
AT _{1B}	gtacacattttcaaaagtgggaacaaaagcttttttcccttttaaaaca	1360	
AT _{1A}	taaccaagcaaagcc.....gtcttgcatataatagat	1562	
AT _{1B}	aattg <u>gagcaaaagccactgtt</u> aaaagccttttttgttgactgaataact	1410	
		4	
AT _{1A}	gatggctagccaaaggaag..agtcaggagctggatggattggtgggtct	1610	
AT _{1B}	gctttaaggacaatgtcagaaattgagtggtgtatggatttggagtta	1460	
AT _{1A}	ggaaaacagttcgctggcagaaatgcaatctcatcagtcctcc.ctttgct	1659	
AT _{1B}	gggaggaggtgtactagcagaaactgaatgtctccagtcctcctcaatt	1510	
AT _{1A}	atgttccttttgatttccacacgtaggtatgtggcccatgctaaatattt	1709	
AT _{1B}	ctgttacttttgatttccacttgaaggtatttagaagctattaatctgt	1560	
		2	
AT _{1A}	aggcaagaaacaagagatggaaatcaaggtcactt <u>gttctgttcaactcc</u>	1759	
AT _{1B}	agacaatcaaaagagatgggaggtcaag.....agttt	1584	

Figure 1. Structures of PCR primers and the nucleotide sequences in the 3'-untranslated regions of AT_{1A} and AT_{1B} receptor cDNAs.

The underlines 1-4 are the sequences of synthetic oligonucleotide primers used for PCR described in Figures 2 and 3.

Mannheim, Mannheim, Germany) and reverse transcriptase (Seikagaku Kogyo, Co. Ltd., Tokyo, Japan). The reaction was carried out by the method described previously (7). After the reaction mixture was heated at 95 °C for 5 min, 1/10 volume of the mixture was directly used for amplification. PCR was carried out in 50 μ l of reaction mixture in the presence of 0.5 μ l of [α -³²P]dATP (185 TBq/mmol; Amersham International Plc., Bucks, UK) by denaturing 94 °C for 30 sec, annealing at 58 °C for 45 sec and elongating at 72 °C for 45 sec. The reaction was carried out by 25 cycles. The employed primers for AT_{1A} (primers 1 and 2) and AT_{1B} (primers 3 and 4) receptor cDNAs are shown in Figure 1. To amplify both subtype cDNAs in a single tube, each set of primers was constructed in the 3'-untranslated regions which were low homology in nucleotide sequences of the two receptor genes. Amplified cDNAs of AT_{1A} and AT_{1B} receptor subtypes gave a 385 base-pairs (bp) and a 204 bp fragments in length, respectively. Ten microlitter aliquot of PCR products were electrophoresed on 8% polyacrylamide gel and the gel was subsequently exposed to an X-ray film (Hyperfilm-MP; Amersham International Plc.) using intensifying screens for 2 hr. The scanning of autoradiographic images was performed with a digital densitometer (DMU-

33C, Toyo Co. Ltd., Osaka, Japan) for the quantification of the amplified cDNA products. Ratios between AT_{1A} and AT_{1B} mRNA expression levels were calculated by arbitrary OD units which were corrected by the length ratio of the two cDNA fragments (AT_{1A}/AT_{1B}= 204/385).

RESULTS AND DISCUSSION

Figure 2 shows autoradiographic images of the amplified cDNA products generated from AT_{1A} and AT_{1B} receptor subtype mRNAs in the various tissues of the control rats. Two forms of AT₁ receptor mRNAs were specifically amplified and detected in all tissues examined. In the aorta, heart, kidney, testis, cerebrum and cerebellum, ratios between AT_{1A} and AT_{1B} mRNA expression levels (AT_{1A}/AT_{1B} ratios) revealed approximately 1~2 (Table 1). Although, in the lung and liver, AT_{1A} receptor mRNA was predominantly expressed (AT_{1A}/AT_{1B} ratios were 4.08 and 8.50, respectively), AT_{1B} mRNA was predominantly expressed in the adrenal gland and pituitary gland (AT_{1A}/AT_{1B} ratios were 0.54 and 0.32, respectively). Kakar et al. (5, 6) reported that AT_{1B} was predominantly expressed in the adrenal gland and pituitary gland in the rat, and they speculated that AT_{1B} receptor mediates secretions of aldosterone from the adrenal gland and ACTH and prolactin from the pituitary gland.

The effect of sodium depletion on the expression of AT_{1A} and AT_{1B} receptor mRNAs was investigated. We compared expression levels of AT_{1A} and AT_{1B} receptor mRNAs between the control and sodium-depleted




Figure 2. Autoradiographic images of the amplified cDNA products generated from tissue AT_{1A} and AT_{1B} receptor mRNAs of the control rats.

Ad, adrenal gland; K, kidney; H, heart; Ao, aorta; Lu, lung; Li, liver; T, testis; P, pituitary gland; Cr, cerebrum and Cl, cerebellum. *AT_{1A} cDNA product (385 base-pairs) and **AT_{1B} cDNA product (204 base-pairs) generated from 2 μ g of tissue total RNAs were observed in each lane.

Table 1. Comparison with relative amounts of AT_{1A} and AT_{1B} receptor mRNAs in the various tissues of Wistar rats

tissues	relative amounts of mRNAs [†]		AT _{1A} /AT _{1B} [§]
	AT _{1A} mRNA	AT _{1B} mRNA	
adrenal gland	1.0	1.0	0.54
aorta	1.1	0.6	1.02
heart	0.9	0.3	1.75
kidney	1.1	0.3	1.83
lung	0.9	0.1	4.08
liver	1.6	0.1	8.50
testis	1.7	0.6	1.45
pituitary gland	0.9	1.5	0.32
cerebrum	1.2	0.5	1.40
cerebellum	0.3	0.1	1.72

[†]Relative amounts of tissue AT_{1A} and AT_{1B} mRNA are expressed as mean ratios in comparison with the corresponding mRNA levels in the adrenal gland (n=3). [§]AT_{1A}/AT_{1B}= mean ratios between AT_{1A} and AT_{1B} mRNA levels in the control rat tissues (n=3).

groups. We failed to detect significant differences in the levels of both AT_{1A} and AT_{1B} receptor mRNAs in 10 different rat tissues after treatment with sodium depletion in comparison with the control group. This result suggests that both AT_{1A} and AT_{1B} receptors may not mediate fluid homeostasis during the altered sodium intake in the adrenal gland or pituitary gland. Iwai et al. (8) reported that sodium depletion positively modulated the expression of AT₁ receptor (AT_{1A}+AT_{1B}) gene in the adrenal gland (2.3-fold increase compared with control rats). However, we failed to detect an increase in the levels of adrenal AT₁ receptor mRNA. This discrepancy will be due to the differences in a degree of sodium depletion and/or the method of measurement for AT₁ receptor mRNA. Recently, Sandberg et al. (9) cloned a novel Ang II receptor (AT₃) which was most abundant in the adrenal cortex and pituitary gland in the rat. They suggested that AT₃ receptor could be mainly regulated during altered sodium intake and could mediate the fluid homeostasis. However, AT₃ receptor reported by Sandberg et al. is very similar to AT_{1B} in respect to the nucleotide sequence in the coding region and the tissue distribution.




Figure 3. Changes in expression levels of AT_{1A} and AT_{1B} receptor mRNAs after treatment with sodium depletion or with an AT₁ receptor specific antagonist, TCV 116.

Ad, adrenal gland; H, heart and Ao, aorta. Left lane, control group; middle lane, sodium-depleted group and right lane, TCV 116-treated group. *AT_{1A} cDNA product (385 base-pairs) and **AT_{1B} cDNA product (204 base-pairs) generated from 2 μ g of tissue total RNAs were observed in each lane.

Next, the effect of an AT₁ receptor specific antagonist, TCV 116, on the expression of AT₁ receptor mRNAs in the adrenal gland, heart and aorta was studied to examine whether both AT_{1A} and AT_{1B} receptors depend on the activity of the RAAS. Levels of both AT_{1A} and AT_{1B} receptor mRNAs were significantly decreased in the heart (AT_{1A}; 33% and AT_{1B}; 33% of the control level, $p < 0.01$) and aorta (AT_{1A}; 48% and AT_{1B}; 67% of the control level, $p < 0.05$) by treatment with TCV 116 for one week (Fig. 3). Interestingly, although AT_{1A} receptor mRNA did not change in the adrenal gland after treatment with TCV 116, the level of AT_{1B} receptor mRNA was significantly decreased by treatment with TCV 116 (35% of the control level, $p < 0.01$). Iwai et al. (10) reported that administration of Dup 753, an AT₁ receptor antagonist, reduced the expression level of AT₁ receptor mRNA (50% of the control level) and the prolonged infusion of Ang II increased the expression level of this receptor mRNA (240% of the control level) in the adrenal gland. Down-regulation of TCV 116 or Dup 753 on the expression of AT₁ receptor mRNA was mainly caused by reducing the expression level of AT_{1B} receptor mRNA which depended on the activity of the RAAS in the adrenal gland. However, in other tissues, there were no significant differences in the levels of AT₁ receptor mRNAs between TCV 116-treated group and the control group.

In conclusion, a simplified and sensitive method for measuring AT_{1A} and AT_{1B} receptor mRNAs was established and the expression levels of the two receptor mRNAs in the various rat tissues were clearly demonstrated. The expression levels of both AT_{1A} and AT_{1B} receptor mRNAs were down-regulated by treatment with an AT₁ receptor specific antagonist in the aorta and heart, and the expression level of AT_{1B} receptor mRNA was mainly down-regulated by the treatment in the adrenal gland. However, the expression levels of AT₁ receptor mRNA did not change after treatment with sodium depletion in the all tissues. These results suggest that the expression level of AT_{1B} receptor mRNA mainly depends on the RAAS in the adrenal gland, and both AT_{1A} and AT_{1B} receptors mediate the contraction and hypertrophy in cardiovascularities via the RAAS.

ACKNOWLEDGMENTS

We thank Takeda Chemical Industries, Ltd. (Osaka, Japan) for supplying TC_V 116 and Miss Mizuho Takaichi for her technical assistance. This work was supported in part by a Research Grant for Cardiovascular Disease (2A-3) from the Ministry of Health and Welfare, Japan.

REFERENCES

1. Peach, M. (1977) *J. Physiol. Rev.* **57**, 313-370.
2. Bumpus, F.M., Catt, K.J., Chiu, A.T., De Gasparo, M., Goodfriend, T., Husain, A., Peach, M.J., Taylor, Jr., D.G., and Timmermans, P.B.M.W.M. (1991) *Hypertension* **17**, 720-721.
3. Sasaki, K., Yamano, Y., Bardhan, S., Iwai, N., Murray, J.J., Hasegawa, M., Matsuda, Y., and Inagami, T. (1991) *Nature* **351**, 230-233.
4. Murphy, T.J., Alexander, R.W., Griendling, K.K., Runge, M.S., and Bernstein, K.E. (1991) *Nature* **351**, 233-236.
5. Kakar, S.S., Sellers, J.C., Devor, D.C., Musgrove, L.C., and Neill, J.D. (1992) *Biochem. Biophys. Res. Commun.* **183**, 1090-1096.
6. Kakar, S.S., Riel K.K., and Neill, J.D. (1992) *Biochem. Biophys. Res. Commun.* **185**, 688-692.
7. Okura, T., Kitami, Y., Iwata, T., and Hiwada, K. (1991) *Biochem. Biophys. Res. Commun.* **179**, 25-31.
8. Iwai, N., Yamano, Y., Chaki, S., Konishi, F., Bardhan, S., Tibbetts, C., Sasaki, K., Hasegawa, M., Matsuda, Y., and Inagami, T. (1991) *Biochem. Biophys. Res. Commun.* **177**, 299-304.
9. Sandberg, K., Ji, H., Clark, A.J.L., Shapira, H., and Catt K.J. (1992) *J. Biol. Chem.* **267**, 9455-9458.
10. Iwai, N. and Inagami, T. (1992) *Biochem. Biophys. Res. Commun.* **182**, 1094-1099.